Erlotinib (Tarceva) - ONA
Links shared publicly online about this topic.
- 773total visits
Erlotinib (Tarceva) - ONA
View full resource at oncologynurseadvisor.com
Tags: Pancreatic Disease, Cancer, Pancreatic Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Tarceva
Most Recently Shared on October 26, 2010 at 1:51 pm By:
Erlotinib (Tarceva) http://goo.gl/fb/TCSeW
ELCC 2012: New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
ecancer.org — “ELCC 2012: New analysis helps guide use of erlotinib in advanced non-small cell lung cancer” View full resource at ecancer.org
Most Recently Shared on April 18, 2012 at 2:11 pm By:
ecancer Oncology and Health News
#ELCC News: New analysis helps guide use of erlotinib in advanced non-small cell lung cancer http://t.co/g4aoiLZc #lungcancer
Oncology Medical Article | Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
mdlinx.com — “Oncology Medical Article: Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer” View full resource at mdlinx.com
Most Recently Shared on March 15, 2012 at 9:36 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotini... http://t.co/OJ6TH0o9 #oncology
Gastroenterology Medical Article | Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer
mdlinx.com — “Gastroenterology Medical Article: Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer” View full resource at mdlinx.com
Most Recently Shared on March 15, 2012 at 3:52 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Pre... http://t.co/efauGhuM #GI
Oncology Medical Article | Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
mdlinx.com — “Oncology Medical Article: Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma” View full resource at mdlinx.com
Most Recently Shared on March 14, 2012 at 8:38 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma: Journal of Neuro-... http://t.co/OLxZgrGF #oncology
Oncology Medical Article | Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
mdlinx.com — “Oncology Medical Article: Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease” View full resource at mdlinx.com
Most Recently Shared on March 14, 2012 at 8:07 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma pati... http://t.co/V0x2TPZZ #oncology
Effectiveness of erlotinib in advanced non-small c... [Onkologie. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on February 20, 2012 at 11:25 am By:
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatme... http://t.co/FI2xT39G
Erlotinib better for treatment of non-small cell lung cancers associated with altered forms of EGFR protein
news-medical.net — “Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer's cells resistant to cancer drugs.” View full resource at news-medical.net
Most Recently Shared on January 11, 2012 at 12:38 pm By:
Lung Cancer News: Erlotinib better for treatment of non-small cell lung cancers associated with altered forms of... http://t.co/eIX5kRzW
Syndax Pharmaceuticals, Ventana Medical Systems to Develop Companion Diagnostic Test for Lung Cancer | IVD Technology
ivdtechnology.com — “Syndax Pharmaceuticals Inc. and Ventana Medical Systems Inc. have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax’s proprietary lead molecule entinostat.” View full resource at ivdtechnology.com
Most Recently Shared on January 9, 2012 at 7:42 pm By:
IVD Technology Health Magazine
Syndax Pharmaceuticals, Ventana Medical Systems to Develop Companion Diagnostic Test for Lung Cancer http://t.co/qVXrItLx
Wasif Saif, MD, MBBS, Authors Study in Anticancer Research, Mar 2011 | Columbia University Department of Surgery Blog
columbiasurgery.net — “In an article published in Anticancer Research in March 2011, M. Wasif Saif, MD, MBBS, describes previously undocumented benefits on the use Erlotinib (Tarceva)” View full resource at columbiasurgery.net
Most Recently Shared on October 21, 2011 at 10:15 am By:
Study finds that pancreatic cancer drug helps overcome resistance to chemotherapy. http://t.co/U798pYJL #pancreaticcancer
Roche lung cancer drug receives Philippine FDA approval | MALAYA Business Insight News Online
malaya.com.ph — “Pharmaceutical company Roche announced this week that the Philippine Food and Drug Administration (FDA) has approved its oral drug erlotinib as first line therapy for people with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.” View full resource at malaya.com.ph
Most Recently Shared on October 9, 2011 at 5:43 pm By:
Roche lung cancer drug receives Philippine FDA approval: Pharmaceutical company Roche announced this week that t... http://t.co/anDtoZIq
Oncology Article | Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
mdlinx.com — “Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer” View full resource at mdlinx.com
Most Recently Shared on September 29, 2011 at 3:11 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer: Cancer http://t.co/GPSLmwfe #oncology
Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer Patients, UK
medicalnewstoday.com — “According to today's announcement by Roche, Tarceva (erlotinib), an oral lung cancer treatment, has been officially licensed as first-line monotherapy for the treatment of patients with advanced” View full resource at medicalnewstoday.com
Most Recently Shared on September 11, 2011 at 8:34 am By:
Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer Patients, UK: According to today's ann... http://t.co/bQRzjFF
Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer Patients, UK - QualityPoint Technologies
qualitypointtech.net — “According to today's announcement by Roche, Tarceva (erlotinib), an oral lung cancer treatment, has been officially licensed as first-line monotherapy for the treatment of patients with advanced forms of non-small cell lung cancer (NSCLC) with a certain mutation, saving them from up-front chemotherapy. The activating mutation is located in the EGFR (epidermal growth factor receptor) protein of NSCLC tumors...” View full resource at qualitypointtech.net
Most Recently Shared on September 11, 2011 at 4:45 am By:
Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer Patients, UK: According to today's anno... http://t.co/iNJvGtn
Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer Patients, UK
medicalnewstoday.com — “According to today's announcement by Roche, Tarceva (erlotinib), an oral lung cancer treatment, has been officially licensed as first-line monotherapy for the treatment of patients with advanced” View full resource at medicalnewstoday.com
Most Recently Shared on September 11, 2011 at 4:43 am By:
MedicalNewsToday: Tarceva (erlotinib) Good Alternative To Chemotherapy For Some Lung Cancer: http://t.co/sv66ODD Full http://t.co/NqqVsQf
Roche’s Tarceva Receives European Approval For First-Line Use In
bioresearchonline.com — “Roche’s Tarceva Receives European Approval For First-Line Use In A Genetically Distinct Type Of Lung Cancer” View full resource at bioresearchonline.com
Most Recently Shared on September 7, 2011 at 8:05 am By:
Roche's Tarceva Receives European Approval For First-Line Use In A Genetically Distinct Type Of Lung Cancer: Per... http://t.co/5gZq1As
Advertisement
